A Phase I Trial of CBT-1 in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Doxorubicin (Primary) ; Tetrandrine (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- Sponsors CBA Pharma
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 Planned initiation date changed from 1 Sep 2017 to 29 Mar 2018.
- 28 Jun 2017 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.